What is Chardan Capital's Estimate for COYA FY2025 Earnings?

Key Points

• Chardan Capital has raised its FY2025 earnings estimate for Coya Therapeutics to ($1.56) per share, slightly improving from a previous estimate of ($1.57), while maintaining a "Buy" rating with a target price of $14.00.
• Coya Therapeutics reported a quarterly loss of ($0.36) per share, missing consensus estimates of ($0.22), alongside revenue of $0.16 million compared to expectations of $0.78 million.
• Currently, Coya Therapeutics has an average rating of "Moderate Buy" among analysts, with a consensus price target of $16.50, despite varied ratings from other firms.

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Investment analysts at Chardan Capital boosted their FY2025 earnings per share estimates for shares of Coya Therapeutics in a research note issued on Wednesday, August 13th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.56) per share for the year, up from their previous forecast of ($1.57). Chardan Capital currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share. Chardan Capital also issued estimates for Coya Therapeutics' FY2026 earnings at ($1.87) EPS.

A number of other research analysts have also commented on COYA. Lake Street Capital began coverage on Coya Therapeutics in a report on Wednesday, July 9th. They set a "buy" rating and a $16.00 price objective on the stock. D. Boral Capital reissued a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, June 9th. Finally, Wall Street Zen lowered Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $16.50.

Coya Therapeutics Stock Performance

Shares of Coya Therapeutics stock traded up $0.27 during trading on Monday, hitting $6.86. 94,743 shares of the stock traded hands, compared to its average volume of 52,070. The stock has a market cap of $114.77 million, a P/E ratio of -5.53 and a beta of 0.26. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The company has a fifty day moving average price of $6.03 and a two-hundred day moving average price of $6.09.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.78 million.

Hedge Funds Weigh In On Coya Therapeutics

Several large investors have recently made changes to their positions in COYA. Geode Capital Management LLC lifted its position in shares of Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock worth $863,000 after purchasing an additional 8,267 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Coya Therapeutics during the 4th quarter worth about $59,000. Tower Research Capital LLC TRC lifted its position in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after purchasing an additional 4,777 shares during the last quarter. Northern Trust Corp lifted its position in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Coya Therapeutics during the 4th quarter worth about $74,000. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.